The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b, open-label, multicenter study of xaluritamig in patients with newly diagnosed localized intermediate- or high-risk prostate cancer in the neoadjuvant setting.
 
David Oh
Consulting or Advisory Role - Maze Therapeutics; Revelation Partners
Research Funding - Allogene Therapeutics (Inst); Amgen (Inst); Merck (Inst); Nutcracker Therapeutics, Inc. (Inst); PACT Pharma (Inst); Parker Institute for Cancer Immunotherapy (Inst); Poseida Therapeutics (Inst); Roche/Genentech (Inst); TCR2 Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on patent claiming methods for the use and optimization of cytotoxic CD4+ T cell therapy for cancer.; Inventor on patent claiming methods to identify patients who will respond to or experience toxicity with cancer immunotherapies based on T cell receptor sequencing.
Travel, Accommodations, Expenses - DAVA Oncology; Poseida Therapeutics; Roche/Genentech
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Eisai; Exelixis; Janssen Oncology; Pfizer
Speakers' Bureau - Astellas Pharma; AVEO; Eisai; Exelixis; Janssen
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Exelixis; Janssen
 
Christopher Darr
Stock and Other Ownership Interests - Bayer
Honoraria - Bayer; Ipsen; Janssen; MSD
Consulting or Advisory Role - Bayer; Ipsen; Janssen
Research Funding - Deutsche Forschungsgemeinschaft (Inst)
Travel, Accommodations, Expenses - Bayer; Ipsen; Janssen; Xeos medical
 
Kevin Zarrabi
Honoraria - Curio Science; OncLive Clinical Congress Consultants
Consulting or Advisory Role - Astex Pharmaceuticals; Eisai; Exelixis; Johnson & Johnson/Janssen
Research Funding - Amgen (Inst); IDEAYA Biosciences (Inst); Janssen (Inst); Vaccitech (Inst)
 
Jessica Hawley
Consulting or Advisory Role - Daiichi Sankyo/Lilly; GlaxoSmithKline; ImmunityBio
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb/Celgene (Inst); Crescendo Biologics (Inst); Janssen Oncology (Inst); Macrogenics (Inst); Vaccitech (Inst)
 
Russell Pachynski
Stock and Other Ownership Interests - Pixie Biosciences, Inc
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Dendreon; Eisai; Exelixis; Janssen Oncology; Macrogenics; Pfizer/EMD Serono; Sanofi; Tolmar Therapeutics
Speakers' Bureau - Bayer; Merck
Research Funding - Bristol Myers Squibb Foundation (Inst); Exelixis (Inst); Janssen Oncology; Pharmacyclics (Inst)
Patents, Royalties, Other Intellectual Property - Compositions comprising chemerin and methods of use thereof; Entitled: METHOD OF CELL-FREE DNA ANALYSIS TO IDENTIFY HIGH-RISK METASTATIC PROSTATE CANCER
Travel, Accommodations, Expenses - Genentech/Roche
 
Scott Tagawa
Stock and Other Ownership Interests - Convergent Therapeutics
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Ambrx; Amgen; Astellas Pharma; Bayer; Bicycle Therapeutics; Blue Earth Diagnostics; Boston Scientific; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Exelixis; Genentech; General Electric; Genomic Health; Gilead Sciences; Hookipa Pharma; Immunomedics; Janssen; Karyopharm Therapeutics; Lantheus Medical Imaging; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Regeneron; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar; TransThera Biosciences
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Janux Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); Telix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Immunomedics; Merck; Sanofi; Telix Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
Yuanquan Yang
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - Exelixis; The whiteoak group; Xencor
Speakers' Bureau - AstraZeneca
Research Funding - Amgen (Inst); Incyte (Inst); Novartis (Inst); Recordati (Inst); Xencor (Inst)
 
Simon Buetikofer
Employment - Amgen
Stock and Other Ownership Interests - Abbott Laboratories; Amgen; Lilly
Honoraria - Amgen
Research Funding - Amgen
Patents, Royalties, Other Intellectual Property - Amgen
Travel, Accommodations, Expenses - Amgen
 
Qing Xia
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Gunhild Von Amsberg
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Janssen; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Eisai; Ipsen; Merck Sharp & Dohme; Roche